The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
|ClinicalTrials.gov Identifier: NCT01655888|
Recruitment Status : Unknown
Verified July 2012 by Michele Maio, Azienda Ospedaliera Universitaria Senese.
Recruitment status was: Recruiting
First Posted : August 2, 2012
Last Update Posted : August 2, 2012
Azienda Ospedaliera Universitaria Senese
Information provided by (Responsible Party):
Michele Maio, Azienda Ospedaliera Universitaria Senese
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||January 2014|
|Estimated Study Completion Date :||January 2015|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, Giannarelli D, Di Giacomo AM, Maio M. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015 Apr;3(4):301-9. doi: 10.1016/S2213-2600(15)00092-2. Epub 2015 Mar 26.